There is currently no treatment for NASH cirrhosis, a progressive disease that may result in liver failure and increased mortality. Currently, the only cure for NASH cirrhosis is a liver transplantation.
The NAVIGATE Study seeks to change this, offering patients and their families the first potential therapy targeted specifically at NASH cirrhosis.
An earlier clinical trial showed that belapectin, the candidate treatment, may prevent the development of esophageal varices in patients with compensated NASH cirrhosis and was well tolerated and appeared safe. While the results were exciting, they need to be confirmed through continued testing on a larger number of patients. “Compensated” means the patient is not yet experiencing the more severe symptoms of NASH cirrhosis. When these severe symptoms occur, the cirrhosis is considered ”decompensated.”
Development of esophageal varices is thought to be an early sign of more serious complications of NASH cirrhosis. Varices happen when scars in the liver block the flow of blood from the digestive system through the liver, causing internal blood vessels to dilate, similar to varicose veins in the legs.
The NAVIGATE Study looks to prevent the development of these varices and provide a better outcome for patients with NASH cirrhosis.
Dr. Pol Boudes, Galectin Therapeutics’s Chief Medical Officer, explains why the NAVIGATE Study in NASH cirrhosis is so innovative.